These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 28447738)
1. Telmisartan suppresses cardiac hypertrophy by inhibiting cardiomyocyte apoptosis via the NFAT/ANP/BNP signaling pathway. Li X; Lan Y; Wang Y; Nie M; Lu Y; Zhao E Mol Med Rep; 2017 May; 15(5):2574-2582. PubMed ID: 28447738 [TBL] [Abstract][Full Text] [Related]
2. Aspirin Attenuates Angiotensin II-induced Cardiomyocyte Hypertrophy by Inhibiting the Ca(2+)/Calcineurin-NFAT Signaling Pathway. Yin Z; Wang X; Zhang L; Zhou H; Wei L; Dong X Cardiovasc Ther; 2016 Feb; 34(1):21-9. PubMed ID: 26506219 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart. Kinoshita H; Kuwahara K; Nishida M; Jian Z; Rong X; Kiyonaka S; Kuwabara Y; Kurose H; Inoue R; Mori Y; Li Y; Nakagawa Y; Usami S; Fujiwara M; Yamada Y; Minami T; Ueshima K; Nakao K Circ Res; 2010 Jun; 106(12):1849-60. PubMed ID: 20448219 [TBL] [Abstract][Full Text] [Related]
4. CD38 promotes angiotensin II-induced cardiac hypertrophy. Guan XH; Hong X; Zhao N; Liu XH; Xiao YF; Chen TT; Deng LB; Wang XL; Wang JB; Ji GJ; Fu M; Deng KY; Xin HB J Cell Mol Med; 2017 Aug; 21(8):1492-1502. PubMed ID: 28296029 [TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells. Liu CJ; Cheng YC; Lee KW; Hsu HH; Chu CH; Tsai FJ; Tsai CH; Chu CY; Liu JY; Kuo WW; Huang CY Mol Cell Biochem; 2008 Jun; 313(1-2):167-78. PubMed ID: 18398669 [TBL] [Abstract][Full Text] [Related]
8. Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling. Chen Y; Yuan J; Jiang G; Zhu J; Zou Y; Lv Q Mol Med Rep; 2017 Oct; 16(4):4545-4552. PubMed ID: 28849081 [TBL] [Abstract][Full Text] [Related]
9. Cardiac-specific overexpression of caveolin-3 attenuates cardiac hypertrophy and increases natriuretic peptide expression and signaling. Horikawa YT; Panneerselvam M; Kawaraguchi Y; Tsutsumi YM; Ali SS; Balijepalli RC; Murray F; Head BP; Niesman IR; Rieg T; Vallon V; Insel PA; Patel HH; Roth DM J Am Coll Cardiol; 2011 May; 57(22):2273-83. PubMed ID: 21616289 [TBL] [Abstract][Full Text] [Related]
10. Astragaloside IV protects against cardiac hypertrophy via inhibiting the Ca2+/CaN signaling pathway. Lu M; Wang H; Wang J; Zhang J; Yang J; Liang L; Maslov LN Planta Med; 2014 Jan; 80(1):63-9. PubMed ID: 24338553 [TBL] [Abstract][Full Text] [Related]
11. Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. Hayashi D; Kudoh S; Shiojima I; Zou Y; Harada K; Shimoyama M; Imai Y; Monzen K; Yamazaki T; Yazaki Y; Nagai R; Komuro I Biochem Biophys Res Commun; 2004 Sep; 322(1):310-9. PubMed ID: 15313208 [TBL] [Abstract][Full Text] [Related]
12. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling. Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855 [TBL] [Abstract][Full Text] [Related]
13. Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca²⁺-mediated calcineurin/NFATc3 and CaMKII signaling cascades. Dai H; Jia G; Liu X; Liu Z; Wang H Environ Toxicol Pharmacol; 2014 Jul; 38(1):263-71. PubMed ID: 24975447 [TBL] [Abstract][Full Text] [Related]
14. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways. Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128 [TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-protein ligase E3a (UBE3A) as a new biomarker of cardiac hypertrophy in cell models. Cheng KC; Li Y; Chang WT; Chen ZC; Cheng JT; Tsai CC J Food Drug Anal; 2019 Jan; 27(1):355-364. PubMed ID: 30648591 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivo. Yang J; Zhu HH; Chen GP; Ye Y; Zhao CZ; Mou Y; Hu SJ Int J Biochem Cell Biol; 2013 Mar; 45(3):657-66. PubMed ID: 23277274 [TBL] [Abstract][Full Text] [Related]
17. Activation of HuR downstream of p38 MAPK promotes cardiomyocyte hypertrophy. Slone S; Anthony SR; Wu X; Benoit JB; Aube J; Xu L; Tranter M Cell Signal; 2016 Nov; 28(11):1735-41. PubMed ID: 27521603 [TBL] [Abstract][Full Text] [Related]
18. NAKα2 inhibits fibrosis formation and protects against cardiomyocyte hypertrophy by suppressing hypertrophy associated molecules and activating LTCC/NCX signaling pathway. Song SS; Tang G; Tang LX; Si LY; Xiong W Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):3021-3033. PubMed ID: 31002153 [TBL] [Abstract][Full Text] [Related]
19. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway. Tan X; Li J; Wang X; Chen N; Cai B; Wang G; Shan H; Dong D; Liu Y; Li X; Yang F; Li X; Zhang P; Li X; Yang B; Lu Y Int J Biol Sci; 2011 Apr; 7(3):383-9. PubMed ID: 21494433 [TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin-3-gallate inhibits angiotensin II-induced cardiomyocyte hypertrophy via regulating Hippo signaling pathway in H9c2 rat cardiomyocytes. Ma Y; Hu Y; Wu J; Wen J; Li S; Zhang L; Zhang J; Li Y; Li J Acta Biochim Biophys Sin (Shanghai); 2019 Apr; 51(4):422-430. PubMed ID: 30877756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]